$NVCT
Nuvectis Pharma, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$19.42
▲After hours+5.14%+$0.950After hours
Nuvectis Pharma, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Flagged at $17.10 at 01:54 PM on Nov 04, then ran to $20.55 +20% that session.
The high is the session peak after our first alert, not a realized trade. Not investment advice.
Why is NVCT up today? It is at $19.42 (+0.41%), and our scanner flagged it 57 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment NVCT spikes, and full due diligence on NVCT — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $NVCT 57 times in the last 30 days. Create a free account to track $NVCT, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
NVCT is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 7 unusual-volume and momentum alerts on NVCT today, peaking at 8.3x its normal volume. Fresh from the SEC: Nuvectis Pharma, Inc.: Q3 FY2026 results, three months to Sep 30, 2026. A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystNuvectis Pharma, Inc.: Q3 FY2026 results, three months to Sep 30, 2026, from the latest SEC filing. Read it →Across every filing on file, supply equal to 65.1% of the tradeable float is in play - 36.7% has already been sold, and 28.4% more can still be issued.
Shelf sizes are dollars, so shares are estimated at today's price.
Recent share offering + active shelf on file — the company raised capital and can raise more
5,000,000 new shares · Priced at $20/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Carson Michael J. Officer | Acquired (grant/award) | +30K 0.09% of company | added 15% | 230K | n/a | Aug 3, 26 |
Bentsur Ron Officer | Bought (open market) | +13K 0.04% of company | added 0.3% | 3.69M | $250K at $20.00 | Jun 30, 26 |
Mosseri Marlio Charles Beneficial Owner (10%) | Bought (open market) | +50K 0.2% of company | added 1.6% | 3.19M | $916K at $18.32 | Jun 30, 26 |
Kaplan Matthew L. Director | Acquired (grant/award) | +35K 0.1% of company | added 28% | 160K | n/a | Jun 11, 26 |
Sanchez Juan Director | Acquired (grant/award) | +35K 0.1% of company | added 45% | 113K | n/a | Jun 11, 26 |
Oliviero James F Iii Director | Acquired (grant/award) | +35K 0.1% of company | added 40% | 123K | n/a | Jun 11, 26 |
Hoberman Kenneth Director | Acquired (grant/award) | +35K 0.1% of company | added 26% | 168K | n/a | Jun 11, 26 |
Carson Michael J. Officer | Acquired (grant/award) | +61K 0.2% of company | added 44% | 200K | n/a | Jan 6, 26 |
Poradosu Enrique Officer | Acquired (grant/award) | +150K 0.5% of company | added 9.1% | 1.81M | n/a | Jan 6, 26 |
Bentsur Ron Officer | Acquired (grant/award) | +150K 0.5% of company | added 4.3% | 3.68M | n/a | Jan 6, 26 |
Shemesh Shay Officer | Acquired (grant/award) | +150K 0.5% of company | added 9.1% | 1.79M | n/a | Jan 6, 26 |
Kaplan Matthew L. Director | Bought (open market) | +11K 0.03% of company | added 9.7% | 125K | $64K at $5.84 | Nov 5, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
NVCT is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 7 unusual-volume and momentum alerts on NVCT today, peaking at 8.3x its normal volume. Fresh from the SEC: Nuvectis Pharma, Inc.: Q3 FY2026 results, three months to Sep 30, 2026. A material company disclosure like this is often the real catalyst behind a move of this size.
NVCT last traded at $19.42, up 0.41% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The NVCT Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged NVCT 57 times in the last 30 days.
NVCT (Nuvectis Pharma, Inc. Common Stock) trades on XNAS, with a market cap of about $602M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge NVCT for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$NVCT discussion
Sign in to ask a question or join the discussion.